Banner Alzheimer's Institute

• Eric Michael Reiman

Sources: reporter.nih.gov

• A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

  Collaborator, Recruiting, 216 people, May 26, 2023

• A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

  Collaborator, Phase 2, Completed, 252 people, Dec 2, 2013

Sources: clinicaltrials.gov

• National Institute on Aging

  R01, Brain Imaging, APOE & the Preclinical Course of Alzheimer's Disease, R01AG031581, $2.1M, 2008–2021, Apr 20, 2018

Sources: reporter.nih.gov

• Accelerated Brain Aging in Amnestic Mild Cognitive Impairment: Relationships with Individual Cognitive Decline, Risk Factors for Alzheimer Disease, and Clinical Progression

  Employment, Jun 23, 2021

• Suspected non-Alzheimer disease pathophysiology--concept and controversy

  Consulting or advice, Jan 18, 2016

Sources: pubmed.ncbi.nlm.nih.gov

• Blood tau fragment linked to cognitive decline in older adults

  Neurology, Oct 23, 2026

• Brain-derived tau tests better flag Alzheimer’s-linked protein

  Brain communications, Oct 18, 2026

• Gene variant linked to lower brain scan signals in women

  Alzheimer's research & therapy, Oct 7, 2026

• Menopause-linked blood proteins tied to cognitive aging in women

  Nature medicine, Sep 23, 2026

• Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers

  Research Square, Aug 19, 2026

• A plasma-based protein signature combining NPTXR, ACHE, and p-tau217 predicts progression to symptomatic Alzheimer's disease

  Alzheimer's & dementia : the journal of the Alzheimer's Association, Aug 14, 2026

• Plasma p-tau217 and NfL predict incident dementia in the community

  medRxiv, Aug 10, 2026

• Plasma Biomarkers for Neocortical Tau Burden

  JAMA neurology, Aug 10, 2026

• Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217

  Alzheimer's & dementia : the journal of the Alzheimer's Association, Aug 6, 2026

• Lifestyle and psychosocial protective factors drive healthy aging and modulate inflammatory and metabolic pathways

  GeroScience, Aug 5, 2026

• Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

  EBioMedicine, Jul 18, 2026

• Effect of Intensive vs Standard Blood Pressure Control According to APOE ε4 Genotype: A Secondary Analysis of SPRINT

  medRxiv : the preprint server for health sciences, Jul 17, 2026

• Blood-based immunophenotyping of T cell profiles in patients with neurodegenerative disorders

  Alzheimer's research & therapy, Jul 17, 2026

• Identifying cognitive subgroups in older adults from community data with hierarchical cluster analysis

  GeroScience, Jul 15, 2026

• CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum

  EBioMedicine, Jul 12, 2026

• Prognostic value of plasma brain-derived pTau

  medRxiv : the preprint server for health sciences, Jul 10, 2026

• Sex-specific associations between astrocytic reactivity and cognitive decline in unimpaired elderly

  bioRxiv : the preprint server for biology, Jul 10, 2026

• Effect of initiating an ARB- versus ACEI-based regimen on dementia risk, a target trial emulation of 2.5 million US Veterans

  medRxiv, Jul 8, 2026

• Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts

  Nature communications, Jul 2, 2026

• Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers

  EBioMedicine, Jun 17, 2026